MA33242B1 - Composes pour le traitement de troubles metaboliques - Google Patents

Composes pour le traitement de troubles metaboliques

Info

Publication number
MA33242B1
MA33242B1 MA34246A MA34246A MA33242B1 MA 33242 B1 MA33242 B1 MA 33242B1 MA 34246 A MA34246 A MA 34246A MA 34246 A MA34246 A MA 34246A MA 33242 B1 MA33242 B1 MA 33242B1
Authority
MA
Morocco
Prior art keywords
metabolic disorders
compounds
treatment
diabetes
exhibit
Prior art date
Application number
MA34246A
Other languages
Arabic (ar)
English (en)
Inventor
Oscar Barba
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
Susan Helen Davis
Karen Lesley Schofield
Thomas Staroske
Alan John William Stewart
David Matthew Withall
Simon Andrew Swain
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA33242B1 publication Critical patent/MA33242B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés thérapeutiques représentés par la formule (I), qui présentent une activité d'agonistes de GPR119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.
MA34246A 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques MA33242B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904287.0A GB0904287D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050442 WO2010103335A1 (fr) 2009-03-12 2010-03-12 Composés pour le traitement de troubles métaboliques

Publications (1)

Publication Number Publication Date
MA33242B1 true MA33242B1 (fr) 2012-05-02

Family

ID=40600949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34246A MA33242B1 (fr) 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques

Country Status (18)

Country Link
US (1) US20120040953A1 (fr)
EP (1) EP2406256A1 (fr)
JP (1) JP2012520284A (fr)
KR (1) KR20110130476A (fr)
CN (1) CN102395584A (fr)
AU (1) AU2010222673A1 (fr)
BR (1) BRPI1009781A2 (fr)
CA (1) CA2754794A1 (fr)
CL (1) CL2011002221A1 (fr)
EA (1) EA201190209A1 (fr)
GB (1) GB0904287D0 (fr)
IL (1) IL215051A0 (fr)
MA (1) MA33242B1 (fr)
MX (1) MX2011009491A (fr)
PE (1) PE20120356A1 (fr)
SG (1) SG174362A1 (fr)
WO (1) WO2010103335A1 (fr)
ZA (1) ZA201107446B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
AR083904A1 (es) * 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) * 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012170867A1 (fr) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Nouveaux composes utilises comme modulateurs de gpr-119
KR101881932B1 (ko) 2011-12-07 2018-07-27 삼성전자주식회사 자기 소자 및 그 제조 방법
CA2878625A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
AU2020313312A1 (en) * 2019-07-15 2022-03-03 Oncoarendi Therapeutics S.A. Substituted amino triazoles useful as chitinase inhibitors
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
AU5700999A (en) 1998-09-01 2000-03-21 Basf Aktiengesellschaft Enhanced functional expression of g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
CN1898235A (zh) * 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006067532A1 (fr) * 2004-12-24 2006-06-29 Prosidion Ltd Agonistes du récepteur couplé aux protéines g
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
EP2308840A1 (fr) 2005-06-30 2011-04-13 Prosidion Limited Agonistes de GPCR
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
WO2007091046A1 (fr) 2006-02-09 2007-08-16 Astrazeneca Ab Composes chimiques
KR20080109075A (ko) 2006-04-06 2008-12-16 프로시디온 리미티드 헤테로사이클릭 ｇｐｃｒ 작용제
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (fr) 2006-06-21 2007-12-27 Pfizer Products Inc. 3-amino-pyrrolidino-4-lactames substitués
BRPI0719941A2 (pt) * 2006-12-06 2014-04-22 Smithkline Beecham Corp Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica
KR20090101278A (ko) 2006-12-22 2009-09-24 인더스트리얼 리서치 리미티드 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체
EP2114936A1 (fr) 2007-01-04 2009-11-11 Prosidion Limited Agonistes de gpcr pipéridiniques
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
ES2373181T3 (es) 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
EP2200609A1 (fr) 2007-09-10 2010-06-30 Prosidion Limited Composés pour le traitement de troubles métaboliques
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
KR101136774B1 (ko) 2007-10-18 2012-04-19 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 금속 피복 폴리이미드 복합체 및 그 복합체의 제조 방법 그리고 전자 회로 기판의 제조 방법
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
KR20110036609A (ko) 2008-07-10 2011-04-07 프로시디온 리미티드 피페리디닐 ｇｐｃｒ 작용제
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
ES2387865T3 (es) 2008-07-10 2012-10-03 Prosidion Ltd Agonistas de GPCR de piperidina

Also Published As

Publication number Publication date
IL215051A0 (en) 2011-11-30
PE20120356A1 (es) 2012-04-16
EP2406256A1 (fr) 2012-01-18
CL2011002221A1 (es) 2012-07-06
BRPI1009781A2 (pt) 2016-03-08
US20120040953A1 (en) 2012-02-16
MX2011009491A (es) 2011-10-11
SG174362A1 (en) 2011-11-28
CA2754794A1 (fr) 2010-09-16
KR20110130476A (ko) 2011-12-05
CN102395584A (zh) 2012-03-28
ZA201107446B (en) 2012-06-27
GB0904287D0 (en) 2009-04-22
WO2010103335A1 (fr) 2010-09-16
AU2010222673A1 (en) 2011-11-03
EA201190209A1 (ru) 2012-04-30
JP2012520284A (ja) 2012-09-06

Similar Documents

Publication Publication Date Title
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA201000046A1 (ru) Замещенные имидазогетероциклы
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
TW200612911A (en) Compounds for the treatment of inflammatory disorders
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
TW200612926A (en) Compounds and compositions as ppar modulators
TW200736247A (en) Compounds for the treatment of inflammatory disorders
MA33428B1 (fr) Agonistes du gpr119
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
EA201291236A1 (ru) Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
JO2686B1 (en) Vehicles
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119